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Abstract
Background: The commonest histological type of renal cancer, clear cell renal cell carcinoma (cc RCC), is
associated with genetic and epigenetic changes in the von Hippel-Lindau (VHL) tumour suppressor. VHL
inactivation leads to induction of hypoxia-inducible factors (HIFs) and a hypoxic pattern of gene expression.
Differential levels of specific microRNAs (miRNAs) are observed in several tumours when compared to normal
tissue. Given the central role of VHL in renal cancer formation, we examined the VHL-dependent regulation of
miRNAs in renal cancer.
Methods: VHL-dependent miRNA expression in cc RCC was determined by microarray analysis of renal cell line
RCC4 with mutated VHL (RCC4-VHL) and reintroduced wild-type VHL (RCC4 + VHL). Five miRNAs highly
upregulated in RCC4 + VHL and five miRNAs highly downregulated in RCC4 + VHL were studied further, in
addition to miR-210, which is regulated by the HIF-VHL system. miRNA expression was also measured in 31 cc RCC
tumours compared to adjacent normal tissue.
Results: A significant increase in miR-210, miR-155 and miR-21 expression was observed in the tumour tissue. miR-
210 levels also showed a correlation with a HIF-regulated mRNA, carbonic anhydrase IX (CAIX), and with VHL
mutation or promoter methylation. An inverse correlation was observed between miR-210 expression and patient
survival, and a putative target of miR-210, iron-sulfur cluster assembly protein (ISCU1/2), shows reciprocal levels of
mRNA expression in the tumours.
Conclusions: We have identified VHL-regulated miRNAs and found that for some the regulation is HIF-dependent
and for others it is HIF-independent. This pattern of regulation was also seen in renal cancer tissue for several of
these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue.
miR-210 showed marked increases in expression in renal cancer and levels correlated with patient survival. The
inverse correlation between miR-210 levels and ISCU1/2 provides support for the hypothesis that ISCU1/2 is a
target of miR-210 and that it may contribute to the anaerobic respiration seen in renal (and other) tumours.
See Commentary: http://www.biomedcentral.com/1741-7015/8/65
Background
Renal cell carcinoma accounts for 2-3% of malignant
diseases in adults, with an increasing worldwide inci-
dence of over 200,000 new cases and 100,000 deaths per
year [1]. The understanding of the pathogenesis of the
commonest histological type, clear cell renal cell carci-
noma (cc RCC), has been considerably advanced by the
recognition that the gene encoding the von Hippel-Lin-
dau (VHL) protein is defective in patients with VHL
disease and in the majority of sporadic cc RCCs result-
ing in activation of a hypoxic pattern of gene expression
[2,3]. The exposure of cells to hypoxia normally leads to
the coordinated regulation of many genes by the tran-
scription factor hypoxia-inducible factor (HIF). In this
process, the VHL protein functions as an E3 ubiquitin
ligase which recognises and binds to two specific hydro-
xyprolyl residues in HIF-1a and HIF-2a and facilitates
ubiquitination, leading to rapid proteasomal degradation
[4,5]. In the presence of oxygen, HIF-a molecules
undergo prolyl hydroxylation catalysed by three homolo-
gous 2-oxoglutarate-dependent dioxygenases, PHD1,
PHD2 and PHD3 [6]. The protein products of this
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broad array of hypoxically regulated genes have critical
roles in processes such as energy metabolism, angiogen-
esis, growth and apoptosis [5,7,8]. The majority of cc
RCCs exhibit VHL mutations and/or silencing by
methylation, which leads to enhanced HIF action and a
hypoxic pattern of gene expression [2,3]. VHL also has a
number of other important functions that may have
tumour suppressor effects (for review, see [9]).
Many nonrenal cancers are also characterised by
hypoxia, enhanced HIF levels and increased expression
of hypoxically regulated genes which correlate both
with tumour aggression and patient outcome [4].
Recently, comprehensive gene arrays have emphasised
the dominant role of the HIF-VHL transcriptional sys-
tem and the HIF peptidyl hydroxylases in the regula-
tion of gene expression by hypoxia [7] and have
characterised HIF-dependent and HIF-independent
pathways of transcriptional regulation in VHL-deficient
cells. However, other mechanisms of gene regulation
by hypoxia include control of mRNA stability, regula-
tion of mRNA translation, global influences on the
transcriptional machinery and regulation mediated by
microRNAs (miRNAs) [10].
miRNAs are noncoding RNA oligonucleotides that
function as important regulators of gene expression. Dif-
ferential levels of specific miRNAs have been observed
in several tumour types when compared to normal tis-
sue [11,12]. In addition, global reductions in miRNA
expression are a feature of many cancers, miRNA gene
copy number variation appears common in cancer, and
overexpression of miRNAs can contribute to oncogen-
esis [13-15]. mRNA targets of these miRNAs include
genes encoding proteins with roles in apoptosis, cell
cycle and growth (for review, see [16]). Furthermore,
certain tumour suppressors such as p53 can directly
influence miRNA production [17], and gene polymorph-
isms of components of the miRNA biogenesis machin-
ery have been associated with renal cell carcinoma
susceptibility [18]. The precise mechanisms underlying
inducible production of miRNAs, the role of tumour
suppressors, such as VHL, in miRNA regulation and the
effects of the HIF-VHL system on miRNA activity
require further definition, as does the contribution of
VHL-dependent alterations in miRNA abundance to the
pathogenesis of renal cancers.
To determine the possible role of miRNAs in hypoxic
gene regulation and to examine for hypoxically regulated
miRNAs that may have relevance to tumour pathogen-
esis, we have surveyed changes in miRNA expression
levels in response of breast cancer cells to hypoxia and
characterised the hypoxic regulation of one specific
human miRNA (miR-210) [19,20]. Given the link
between hypoxia and miR-210 regulation and the
recognition of particular alterations in miRNA expres-
sion in cancer, we hypothesised that levels of miR-210
expression in cancer would correlate with degree of
hypoxia and tumour behaviour. To test this hypothesis,
we have recently examined the expression of this
hypoxically induced miRNA in human breast cancers
and found a striking association with breast cancer
prognosis [19,20]. Given the central role of VHL in
hypoxic gene regulation and in renal cancer formation,
we wished to examine the VHL-dependent regulation of
miRNAs in renal cancer. miRNA dysregulation has been
observed in renal cancer, and miR-210 has been identi-
fied as a hypoxia and VHL-regulated miRNA in renal
cancer cells [21-23]. We wished to understand the
mechanism underlying such alterations, examine the
extent to which VHL-mediated alterations in miRNAs
were HIF-dependent or independent and examine for
the utility of miRNA alterations in renal cancer
diagnosis.
Methods
Cell lines
The renal cancer cell line RCC4 stably transfected with
either an empty vector or a vector encoding VHL was
used in this study [24]. Cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum (Invitrogen, Newcastle, NSW, Australia).
All experiments were conducted in triplicate with inde-
pendent cell cultures.
Cell treatments
Treatment of cells with dimethyloxalylglycine (DMOG)
(Biomol International, Plymouth Meeting, PA, USA)
involved supplementing cell media with 1 mM DMOG
diluted in phosphate-buffered saline (PBS) for 24 hours
[25,26].
For HIF-1a and HIF-2a small interfering RNA
(siRNA) treatments, RCC4-VHL cells were seeded at 30-
50% confluency and grown for 24 hours. Cells were then
transfected with 50 mM HIF-1a (sense 5’-CUGAUGAC
CAGCAACUUGAdTdT-3’ and antisense 5’-UCAAGUU
GCUGGUCAUCAGdTdT-3’; Dharmacon, Lafayette,
CO, USA), HIF-2a siRNA (sense 5’-CAGCAUCUUU
GAUAGCAGUdTdT-3’ and antisense 5’-ACUGCUAU
CAAAGAUGCUGdTdT-3’; Dharmacon) [19] and Accell
negative control kit (Dharmacon) using Lipofectamine
2000 (Invitrogen). After 48 hours, RNA and protein
were extracted.
For miR-210 overexpression studies, 20 nM miR-210
oligonucleotide duplex (sense 5’-CUGUGCGUGUGA
CAGCGGCUGA-3’ and antisense 5’-AGCCGCUGUCA
CACGCACAGUU-3’; GenePharma, Shanghai, China)
and 20 nM mimic negative control (sense 5’-UUCUCC
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GAACGUGUCACGUTT-3’ and antisense 5’-ACGUGA
CACGUUCGGAGAATT-3’; GenePharma) were trans-
fected into RCC4 + VHL cells seeded at 30-50% con-
fluency. RNA was harvested after 48 hours.
For miR-210 repression studies, 20 nM miR-210
siRNA (5’-UCAGCCGCUGUCACACGCACAG-3’; Gen-
ePharma) and 20 nM miRNA inhibitor negative control
(5’-UCUACUCUUUCUAGGUUGUGA-3’; GenePharma)
were transfected into RCC4-VHL cells seeded at 30-50%
confluency. RNA was harvested after 48 hours.
Microarray
The miRNA microarrays consisted of 1488 antisense
miRNA oligonucleotide probes (miRCURY LNA micro-
RNA probe set, catalog no. 208010 V8.1; Exiqon, Vad-
baek, Denmark) printed in duplicate onto epoxide-
coated microarray slides (Corning Life Sciences, Acton,
MA, USA). For detection on the array, 5 μg of total
RNA was labelled by the ligation of a fluorescently mod-
ified RNA dimer [27]. Two sample (dual colour) compe-
titive hybridizations were performed using Cy3- and
Cy5-labelled sample pairs.
Hybridisation was performed for 16 hours at 56°C
under LifterSlips (Erie Scientific, Portsmouth, NH, USA)
in 1× Exiqon hybridization buffer (catalog no. 208020)
(Exiqon, Vadbaek, Denmark) in a total volume of 25 μL.
Slides were placed in Corning hybridization chambers
and protected from light for the 16-hour incubation.
Slides were washed using dilutions of the Exiqon Wash
Buffer kit (catalog no. 208021) as recommended by the
manufacturer. Slides were scanned at 10-μm resolution
with a Genepix 4000B Scanner (Molecular Devices,
Union City, CA, USA).
Median spot pixel intensity values in scanned images
were extracted using the Spot v3 plugin (CSIRO, Clay-
ton South, VIC, Australia) for the statistical environ-
ment R. After subtraction of background intensities and
global loess normalisation, mean intensities were log2
transformed and ratios (Cy5/Cy3) were obtained. Differ-
entially expressed miRNAs were determined using linear
models and empirical Bayesian moderation of standard
errors (LIMMA R package, WEHI, Melbourne, VIC,
Australia; [28]).
Immunoblotting
Whole cell extracts were resolved by standard polyacry-
lamide gel electrophoresis and electroblotted onto poly-
vinylidene difluoride membrane (Millipore, Bedford,
MA, USA). Primary antibodies used were mouse mono-
clonal anti-HIF-1a (610958; BD Transduction Labora-
tories, San Diego, CA, USA) and rabbit polyclonal anti-
HIF-2a (NB100-122; Novus Biologicals, Littleton, CO,
USA). Horseradish peroxidase-conjugated secondary
antibodies goat anti-rabbit IgG and donkey anti-mouse
IgG (Immunopure; Thermo Scientific, Rockford, IL,
USA) were used in conjunction with the ECL system
(SuperSignal West Pico; Pierce, Rockford, IL, USA) to
visualise bands using an ImageQuant LAS 4000 system
(GE Healthcare Life Sciences, Uppsala, Sweden).
Patient samples
Thirty-one patients with cc RCC treated in Adelaide,
South Australia, Australia, between 1997 and 2006 were
studied. Samples were obtained from the Flinders Medi-
cal Centre/Repatriation General Hospital Tissue Bank
facility. Ethical approval for analysis of samples was
obtained from the Flinders Clinical Research Ethics
Committee (FCREC). All patients gave informed, signed
consent. The clinical details of the patients are sum-
marised in Table 1.
Quantitative real-time PCR for miRNAs, CAIX and ISCU1/2
miRNA expression was assessed by relative quantitation
real-time PCR (qPCR) using TaqMan microRNA assays
(Applied Biosystems, Foster City, CA, USA).RNA was
Table 1 Summary of the clinical characteristics of 31
patients with cc RCC
Clinical Features Number of patients
Sex
Female 6
Male 25
Age (yr)
Median 67
Range 31-88
Grade
1 3
2 16
3 10
4 2
TMN Stage
pT1 5
pT2 6
pT3a 8
pT3b 2
pT4 1
Unknown 9
Size (mm)
21-50 18
51-100 7
101-150 4
151-200 0
201-250 1
Unknown 1
Pathological details of cc RCC tumours according to Fuhrman’s grading
system and the International Union Against Cancer (UICC) TNM classification.
The size of tumours (in mm) and the age and gender of the 31 patients is
also shown.
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extracted from cells and tissue using TRIzol reagent
(Invitrogen) according to the manufacturer’s instruc-
tions. RNA quantity and quality was determined using a
Nanodrop-8000 spectrophotometer (Nanodrop Technol-
ogies, Wilmington, DE, USA). cDNA was synthesised
from 5 ng of total RNA using TaqMan miRNA-specific
primers and the TaqMan microRNA reverse transcrip-
tion kit (Applied Biosystems). qPCR was performed
using the Corbett Rotor-gene 2000. Each PCR was per-
formed in triplicate and contained 1 μl of reverse tran-
scription product, 1× TaqMan Universal PCR Master
Mix No AmpErase UNG and 0.5 μl of primer and
hydrolysis probe mix of the TaqMan microRNA assay
(assay IDs: miR-210: 000512, miR-155: 000479, miR-21:
000397, miR-31: 001100, miR-20a: 000580, miR-18a:
002422, miR-17: 000393, let-7i: 002221, miR-193b:
001010; Applied Biosystems). The 10-μl reactions were
incubated at 95°C for 10 minutes, followed by 40 cycles
of 95°C for 15 seconds and 60°C for 60 seconds. Results
were normalised to the expression of the small nuclear
RNA gene RNU6B (assay ID: 001093; Applied Biosys-
tems) for cell samples and an average of the small
nucleolar RNAs RNU43 and RNU48 (assay IDs: 001095
and 001006, respectively; Applied Biosystems) expres-
sion levels for tissue samples, as no significant variation
of expression was found between tumour and normal
tissue. Data were generated and analysed using Corbett
Rotorgene software (version 5.0.61) (Corbett Research,
Sydney, NSW, Australia) and the Relative Expression
Software Tool (REST) program (Corbett Research, Syd-
ney, NSW, Australia) [29].
For mRNA expression studies, 1 μg of RNA was reverse
transcribed following DNase treatment (New England
Biolabs, Beverly, MA, USA) using M-MLV Reverse Tran-
scriptase RNase H minus, Point mutant (Promega, Madi-
son, WI, USA) and Oligo dT(15) primers. Carbonic
anhydrase IX (CAIX) mRNA expression was assessed by
qPCR according to the SYBR Green protocol (Applied
Biosystems). The following primers were used to amplify
CAIX (each at 0.25 μM per reaction): forward 5’-CC
TCTCCCGGAACTGAGCCTAT-3’ and reverse 5’-TG
TTCTGAGCCTGGGTGATCTG-3’ [30]. Iron-sulfur
cluster assembly (ISCU1/2) mRNA expression was
assessed by qPCR using the ISCU1/2 TaqMan gene
expression kit (assay ID: Hs00384510_m1; Applied Bio-
systems) according to the manufacturer’s instructions,
and the human b-actin gene was used as a reference
using the following primers (each at 0.25 μM per reac-
tion): forward 5’-TTGCCGACAGGATGCAGAAG-3’
and reverse 5’-GCCGATCCACACGGAGTACT-3’.
VHL sequencing
Mutation analysis of the promoter region, three exons
and associated splice junctions of the VHL gene were
performed by PCR amplification and cycle sequencing.
Genomic DNA was extracted from tumour samples
using the DNeasy kit, spin-column protocol (Qiagen,
Hilden, Germany) according to the manufacturer’s
instructions. DNA was PCR amplified in 50-μl reactions
using AmpliTaqGold (Roche, Branchburg, NJ, USA)
according to the manufacturer’s instructions and the fol-
lowing conditions and primers. Promoter and Exon 1:
Primers forward 5’-TAGCCTCGCCTCCGTTACA-3’
and reverse 5’-GCTTCAGACCGTGCTATCG-3’,
Exon 2: Primers forward 5’-TGATCTCCTGACCTCAT-
GAT-3’ and reverse 5’- GACACCATAACACCTTTA
AC-3’ and Exon 3: Primers forward 5’-TACTGA
GACCCTAGTCTG-3’ and reverse 5’-GGAAGGAAC
CAGTCCTG-3’. PCR primers for exons 1 and 3 were
tagged with universal M13 primers. PCR products were
visualised on agarose gel and purified using ExoSAP-IT
(GE Life Sciences) according to the manufacturer’s
instructions. Cycle sequencing was performed using uni-
versal M13 forward and reverse primers for exons 1 and
3 and the PCR primers for exon 2 and standard BigDye
(Applied Biosystems) chemistry. Sequencing products
were purified using Agencourt CleanSEQ Dye Termina-
tor Removal (Beckman Coulter, Beverley, MA, USA)
according to the manufacturer’s instructions and ana-
lysed on an Applied Biosystems 3730 analyser.
Sequence traces were compared to the National Cen-
ter for Biotechnology Information (NCBI) reference
sequence NM_000551.2 using Mutation Surveyor (Soft-
Genetics, State College, PA, USA). Splice site variants
were analysed using the Berkeley Drosophila Genome
Project (BDGP) http://www.fruitfly.org/about/index.
html, NetGene2 http://www.cbs.dtu.dk/services/Net-
Gene2/ and GeneSplicer http://www.cbcb.umd.edu/soft-
ware/GeneSplicer/gene_spl.shtml splice site predictors.
Human Genome Variation Society (HGVS) nomencla-
ture was used for variant identification [31].
VHL promoter methylation analysis
Bisulphite treatment followed by methylation-specific
PCR (MSP) was used to analyse the methylation status
of the VHL promoter [32]. Genomic DNA was subjected
to bisulphite treatment using an EpiTect Bisulfite kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. The following primers were used for
amplifying the VHL promoter: Unmethylated-specific
(expected size 165 bp) forward 5’-GTTGGAGGA
TTTTTTTGTGTATGT-3’, reverse 5’-CCCAAACCA
AACACCACAAA-3’, and methylated-specific (expected
size 158 bp) forward 5’-TGGAGGATTTTTTTGCG
TACGC-3’, reverse 5’-GAACCGAACGCCGCGAA-3’
[33]. The PCR mixture contained 1× PCR buffer (New
England Biolabs), deoxynucleotide triphosphates (each at
2.5 mM), primers (each at 0.8 mM), 50 ng modified
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DNA and 2.5 U of Taq DNA polymerase (New England
Biolabs) added after a 5-minute at 95°C hot start, in a
total reaction volume of 50 μl. Reactions were carried
out on a GeneAmp PCR system 9700 thermocycler
(Applied Biosystems) for 35 cycles (30 seconds at 95°C,
30 seconds at 47°C and 30 seconds at 72°C), followed by
a final extension of 4 minutes at 72°C. Each PCR was
loaded (20 μl) onto a 3% agarose gel containing ethi-
dium bromide and visualised under UV light.
Statistical analysis
All statistical analysis was done using PASW Statistics
17 (Somers, NY, USA). The Mann-Whitney U test was
used to assess the difference between miRNA expression
in RCC4 ± VHL cells, treated/untreated cells and
tumour/normal adjacent tissue. Spearman’s r correlation
coefficient was used to assess correlations between
miRNA expression and ISCU1/2 and CAIX expression
and for the correlation of miR-210, miR-155, miR-21,
miR-18a, let-7i, ISCU1/2 and CAIX expression with sur-
vival, tumour size, grade and tumour node metastasis
(TNM) stage. Kaplan-Meier log-rank (Mantel-Cox) ana-
lysis was undertaken to assess overall survival, miR-210
expression and TNM stage. Results were considered sta-
tistically significant at P ≤ 0.05.
Results and Discussion
VHL regulation of miRNA expression in RCC4 cells
To test the hypothesis that there are specific alterations
in miRNA expression in VHL-dependent renal cancer,
we studied parallel cultures of renal carcinoma cells
with mutated VHL (RCC4-VHL) and reintroduced wild-
type VHL (RCC4 + VHL). We analysed these cells for
expression of both HIF-1a and HIF-2a and, in keeping
with previous studies [24], confirmed high levels of HIF
in cells lacking functional VHL (Additional file 1). We
undertook a microarray analysis of miRNA expression
in RCC4 cells and compared expression in cells with
and without functional VHL (Figure 1).
Whilst the majority of miRNAs showed no substantial
difference in expression, some showed very significant
VHL-dependent differences. miRNAs with a positive
Bayesian log odds value were considered to be differen-
tially expressed (Figure 1). Furthermore, we sought to
confirm these findings by measuring the expression of
the top five up- and downregulated human miRNAs in
RCC4-VHL by qPCR in independent experiments, in
addition to miR-210, which we had previously shown to
be regulated by the HIF-VHL system [34]. Of the
selected downregulated miRNAs, miR-21, miR-31 and
let-7i were found to be slightly repressed 1.9-, 1.7- and
1.4-fold, respectively; P = 0.05 (RCC4-VHL compared to
RCC4 + VHL) (Figure 2a). No TaqMan assay is cur-
rently available to validate miR-663 expression by qPCR,
and the downregulation of miR-720 was not detectable
in our assays. All of the selected upregulated miRNAs,
miR-155, miR-193b, miR-18a, miR-20a and miR-17 (also
known as miR-17-5p), were found to be highly
expressed in cells without functional VHL (13.0-, 5.2-,
3.8-, 3.1- and 2.3-fold, respectively; P = 0.05) (RCC4-
VHL compared to RCC4 + VHL) (Figure 2b). Consistent
with other reports [35], the amplitude of differential
expression was higher than had been assessed with the
microarray platform. Furthermore, the differential
expression of miR-210 was confirmed (16-fold; P = 0.05)
(RCC4-VHL compared to RCC4 + VHL) (Figure 2b).
The results were controlled and normalised by reference
to expression of RNU6B, whose levels we have pre-
viously shown to be unaffected by VHL status and
hypoxia [34].
Although the microarray analysis may not have
detected the expression of all VHL-regulated miRNAs,
the subsequent qPCR validation confirms the existence
of substantial VHL-dependent regulation of multiple
specific miRNAs in cell culture. The VHL-dependent
miRNA expression pattern we observed might be
mediated by enhanced levels of HIF-a proteins or alter-
natively might be due to other effects of VHL. HIF-inde-
pendent functions of VHL have been described in
cellular senescence, microtubule stability and matrix for-
mation [9]. To examine the extent to which this pattern
of VHL-dependent miRNA dysregulation was mediated
by the HIF system, we examined the effects of the prolyl
hydroxylase inhibitor DMOG, which activates HIF and a
HIF-dependent pattern of gene expression [7,26]. We
confirmed this induction of HIF-1a and HIF-2a by
DMOG in the RCC4 + VHL cells (Additional file 1) and
also confirmed the induction of the HIF target, CAIX,
by DMOG in the RCC4 + VHL cells (Additional file 2).
Of the five miRNAs confirmed to be upregulated in
RCC4-VHL cells, only miR-155 and miR-193b were
found to be slightly upregulated in response to DMOG
treatment in RCC4 + VHL (1.6- and 1.5-fold, respec-
tively; P = 0.05) (Figure 3b), although the amplitude of
induction was less than that seen between cells differing
in VHL status. Figure 3a shows that the three miRNAs
(miR-31, miR-21 and let-7i) confirmed to be downregu-
lated in the RCC4-VHL cell line are not downregulated
in response to DMOG treatment of the RCC4 + VHL
cell line. As expected, the expression of miR-210 also
increased with DMOG treatment (15-fold; P = 0.05)
(Figure 3b).
To further explore whether the miRNAs induced in the
absence of VHL are indeed regulated by HIF, we trans-
fected the RCC4-VHL cell line with HIF-1a and HIF-2a
siRNA oligonucleotides. Figure 4 shows that following
treatment to suppress HIF expression, the levels of miR-
210 and miR-155 were decreased in the treated lines
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compared to those treated with a negative transfection
control. HIF-1a siRNA treatment decreased miR-210
and miR-155 levels 1.75- and 2.8-fold, respectively, and
HIF-2a siRNA treatment decreased miR-210 and miR-
155 levels 1.6- and 2.8-fold, respectively (P = 0.05), in
keeping with the results of HIF hydroxylase inhibition
and consistent with a role for HIF in their control.
However, miR-193b did not show any change between
treated and control cells, which may indicate that miR-
193b regulation is only partially mediated by HIF.
Furthermore the lesser effect on miRNA regulation seen
with HIF repression compared to that seen with DMOG
treatment may represent insufficient duration of HIF
repression or incomplete transfection efficiency in these
cells. Taken together, these results suggest that the
induction of several miRNAs in cells lacking VHL is
mediated in large part via HIF induction (miR-210 and
miR-155), whilst the dysregulation of other miRNAs
(miR-31/miR-21/miR-18a/miR-17/let-7i/miR-20a) is
HIF-independent and mediated by other actions of VHL.
Analysis of VHL-dependent miRNA expression in renal
tumours
Given these interesting observations in one particular
renal cancer cell line, we examined whether this signa-
ture of VHL-dependent miRNA dysregulation occurs in
renal tumours. This would provide information about
the extent to which these specific VHL-dependent
miRNA alterations are more widely observed in renal
cancer, with important implications for understanding
renal oncogenesis and developing diagnostic and prog-
nostic markers in renal cancer.
To address the hypothesis that VHL-regulated miR-
NAs are also dysregulated in renal tumours, we exam-
ined the nine miRNAs found to be differentially
expressed between RCC4-VHL and RCC4 + VHL cell
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Figure 1 MicroRNA (miRNA) expression in RCC4 cells assayed by microarray. The x-axis represents the differential expression (M value =
log2) in renal cancer cells with and without von Hippel-Lindau (VHL) disease. The y-axis represents the (Bayesian) probability that miRNA is
differentially expressed. The top five up- and downregulated differentially expressed human miRNAs are labelled. The array was performed using
three independent samples of each cell type.
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lines. The expression of several of these miRNAs was
found to be upregulated in 31 cc RCC tumours com-
pared to adjacent normal tissue (Figure 5). The expres-
sion of each miRNA was normalised to an average of
RNU43 and RNU48 expression, both of which were
found not to be differentially expressed between tumour
and normal tissue (0.96-fold (P = 0.906) and 1.02-fold
(P = 0.746) expression in tumour relative to adjacent
normal tissue, respectively). Figure 5a shows the expres-
sion of miR-210, miR-155 and miR-21, which are
Figure 2 VHL regulation of miRNA expression in RCC4 cells. Expression of VHL-regulated miRNAs was validated by relative quantitation real-
time PCR (qPCR). (a) VHL-dependent downregulation of miR-31, miR-21 and let-7i in RCC4-VHL cells (P = 0.05). (b) VHL-dependent upregulation
of miR-155, miR-210, miR-193b, miR-17, miR-18a and miR-20a in RCC4-VHL (P = 0.05). The expression of the miRNAs was normalised to RNU6B
expression. The mean ± SEM of three independent cell cultures is shown, and each sample was assayed in triplicate.
Neal et al. BMC Medicine 2010, 8:64
http://www.biomedcentral.com/1741-7015/8/64
Page 7 of 17
significantly upregulated in tumour tissue compared to
normal adjacent tissue (8-, 16- and 4-fold, respectively;
P ≤ 0.0001). The expression of three members of the
miR-17-92 cluster in tumour tissue was also examined.
miR-18a was upregulated in clear cell tumour tissue
compared to adjacent normal tissue (1.6-fold; P ≤
0.0001), however, while miR-20a also appeared to be
slightly upregulated (1.3-fold), this was not statistically
significant (P = 0.067). The expression of miR-17 was
not found to be significantly different in tumour com-
pared to normal adjacent tissue (Figure 5b). The miR-
NAs miR-193b and miR-31 were not significantly
Figure 3 miRNA expression in RCC4 + VHL cells following dimethyloxalylglycine (DMOG) treatment. Expression of VHL-regulated miRNAs
in RCC4 + VHL cells in response to DMOG treatment was assessed by qPCR. (a) Expression of miR-31, miR-21 and let-7i is unchanged in
response to DMOG treatment. (b) Expression of miR-210, miR-155 and miR-193b is increased upon treatment with DMOG in RCC4 + VHL cells (P
= 0.05), but the expression of miR-17, miR-18a and miR-20a is unchanged. The expression of the miRNAs was normalised to RNU6B. The mean ±
SEM of three independent cell cultures is shown, and each sample was assayed in triplicate.
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different between tumour and adjacent normal tissue;
however, let-7i was slightly upregulated 1.2-fold in
tumour tissue (P = 0.043) (Figure 5c). Of interest are
four normal tissue samples in Figure 5a which are out-
liers and display miR-210 levels as high as the mean
tumour expression level. It is possible that the normal
kidney tissue taken from these patients was diseased or
hypoxic as a consequence of the adjacent tumour, lead-
ing to abnormally high miR-210 expression levels.
These results show that some of the VHL-regulated
miRNAs, such as miR-210 and miR-155 in cultured
cells, are highly differentially expressed between renal
cancer tissue and normal tissue. However, other miR-
NAs such as miR-31 and miR-193b do not show such
regulation and indeed, somewhat surprisingly, miR-21
and let-7i, which were decreased in cells lacking VHL,
were overexpressed in renal cancer when compared to
normal adjacent renal tissue. This suggests that despite
Figure 4 miRNA expression in RCC4-VHL cells following hypoxia-inducible factor (HIF) small interfering RNA (siRNA) treatment.
Expression of VHL-regulated miRNAs in RCC4-VHL cells in response to HIF-1a and HIF-2a siRNA treatment was assessed by qPCR. (a) Expression
of miR-210 is decreased in response to HIF siRNA treatment in RCC4-VHL cells (P = 0.05). (b) Expression of miR-155 is also decreased upon
treatment with HIF siRNA in RCC4-VHL cells (P = 0.05). The expression of the miRNAs was normalised to RNU6B. The mean ± SEM of three
independent cell cultures is shown, and each sample was assayed in triplicate.
Neal et al. BMC Medicine 2010, 8:64
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VHL regulation at the cellular level, tumour growth and
progression select for enhanced miR-21 and let-7i
expression in tumour cells or other cells within the
renal cancers. The decrease in expression in RCC4-VHL
cells may be an artefact of cell culture resulting from
different selection pressures in culture compared to cc
RCC tumour tissue. Also, there are many mechanisms
that may lead to overexpression of miR-21 in renal can-
cer, and these may not be related to VHL function. The
RCC4 cell line used in this study may not be representa-
tive of the situation in all renal cancers, and in future
studies it would be beneficial to validate these findings
in additional kidney cancer cell lines.
miR-21 has been identified as having oncogenic prop-
erties and is overexpressed in the majority of cancer
types examined [36]. A host of tumour suppressor genes
have now been validated as targets of miR-21 (for
review, see [36]), and recently the suggestion has been
made, on the basis of bioinformatics analysis, that VHL
may be a target of miR-21 [22,37], but this awaits
experimental validation. Our finding that miR-21 is
upregulated in cc RCC tumours is in keeping with two
recent studies profiling miRNA expression in renal can-
cer that have also identified miR-21 as upregulated in cc
RCC tumour tissue compared to normal kidney tissue,
although the increase in expression observed in our
study (fourfold) was higher than previously reported
(2.5- and 1.2-fold) [21,22].
The overexpression of miR-210 in cc RCC has also
recently been reported [21-23]. miR-210 is also overex-
pressed in many other tumour types [16], most notably
breast cancer, in which it was found to be a prognostic
marker [19]. miR-155 is also overexpressed in many
cancers [16] and has been shown to inhibit apoptosis by
targeting tumour protein p53 inducible nuclear protein
1 (TP53INP1) [38]. In addition, O’Connell and others
have found that inositol phosphatase SHIP1 is a target
of miR-155 [39]. Our results are in accord with those of
other studies which have found increased miR-155
expression levels in cc RCC tissue, although the
reported fold increases (3.2- and 6.4-fold) [21,23] were
less than what was found in this series (15-fold).
The differential expression of some members of the
miR-17-92 cluster in cc RCC is particularly interesting,
as overexpression of this miRNA cluster has been impli-
cated in a wide range of cancers and has been shown to
act as an oncogene [13-15]. miR-17-92 has been shown
to play an important role in tumour cell proliferation
and apoptosis [16,40], to negatively regulate HIF-1a
expression [41] and appears to have a critical function
in vascular endothelial growth factor-induced angiogen-
esis [42]. Under normal physiological conditions, miR-
17-92 is involved in the regulation of MYC-induced cell
proliferation by inhibiting E2F1 expression; however,
on
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Figure 5 Expression of VHL-regulated miRNAs in clear cell
renal cell carcinoma (cc RCC) tissue compared to normal
adjacent tissue. Measurements of miRNA expression were
determined by qPCR and normalised to an average of RNU43 and
RNU48 expression. qPCR for each sample was performed in
triplicate. (a) miR-210, miR-155 and miR-21 were all highly
upregulated in tumour tissue compared to normal kidney tissue (P
≤ 0.0001). (b) Expression of three members of the miR-17-92 cluster:
miR-17, miR-18a and miR20a were examined, and miR-18a was
found to be significantly upregulated in tumour tissue (P ≤ 0.0001).
(c) No significant difference in expression was observed for miR-
193b and miR-31; however, let-7i displayed significant upregulation
in tumour tissue (P ≤ 0.043). #P ≤ 0.0001; ##P ≤ 0.05;°outlier (values
between 1.5 and 3 interquartile ranges (IQRs) from the end of box);
*extreme outlier (values more than 3 IQRs from the end of box).
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when miR-17-92 is overexpressed in many cancers, it
can act with MYC to synergistically contribute to
aggressive cancer development [14,43-45]. The overex-
pression of three members of the miR-17-92 cluster,
miR-17, miR-20a and miR-18a, has previously been
reported for cc RCC [21,37]. Our finding that these
three miRNAs are upregulated in the RCC4-VHL cell
line is in accord with findings in these studies; however,
we were unable to confirm the upregulation of miR-17
in tumour tissue or the statistically significant upregula-
tion of miR-20a. This discrepancy may be due to small
sample size, differences in procedure or potential inter-
ference of other cell types in the tumour samples.
Eleven members of the let-7 family have been identi-
fied in the human genome. The family was one of the
earliest tumour suppressor miRNAs identified in cancer,
and some members of the let-7 family can also have
oncogenic roles [46]. The increased expression of one
member of the let-7 family, let-7i, has been reported in
breast cancer [47] and head and neck squamous cell
carcinoma [48], and decreased expression is associated
with chemotherapy resistance and shorter progression-
free survival in late-stage ovarian cancer patients [49].
To the best of our knowledge, this is the first report of
a change in let-7i expression in renal cancer.
The hypoxic and VHL status of the tumour tissue
As some of the miRNAs display HIF-dependent regula-
tion (Figure 3b and Figure 4), we sought to examine
HIF-dependent mRNA expression in the 31 tumour
samples. CAIX is a transcriptional target of HIF-1. Its
expression has previously been shown to be an intrinsic
marker of hypoxia/HIF activation [50] and has been
reported to be a predictor of outcome in renal cancer
[51]. Thus, the expression level of CAIX in the cc RCC
tumour tissue was determined to infer the presence of
hypoxia and/or the likely activation of HIF. Consistent
with this, an undetectable level of expression was
observed in the normal matched adjacent tissue.
Furthermore, a striking positive correlation was found
between CAIX and miR-210 expression (r = 0.527, P =
0.002), as shown in Figure 6. No correlation was
observed between CAIX levels and other VHL-regulated
miRNAs, with the exception of miR-155 which showed
a weak correlation (r = 0.318, P = 0.082). This is consis-
tent with the regulation of miR-155 by VHL through
HIF-1a. These results provide additional support for the
concept that several of the VHL-dependent miRNAs are
at least partially regulated via HIF whilst others are
regulated by HIF-independent mechanisms.
We also analysed miRNA and CAIX expression by
whether the tumours had identifiable VHL defects. The
tumours were analysed for VHL mutations and VHL
promoter methylation status (Additional file 3). It has
been found that biallelic VHL mutations are found in
50-75% of sporadic cc RCC tumours [2,3]. In keeping
with other series, VHL mutations were found in 42% of
clear cell tumours [33], and the VHL promoter was
found to be methylated in 10% of clear cell tumours
[52,53]. We hypothesised that CAIX and HIF-regulated
miRNAs would be indicative of the VHL status of the
tumour, and indeed a significant difference between the
two groups was observed for CAIX and miR-210 expres-
sion. CAIX and miR-210 expression were found to be
significantly increased in tumours with identifiable VHL
mutations, or promoter methylation, compared to
tumours in which we did not identify a mechanism for
suppression of VHL function (P = 0.045 and 0.011; Fig-
ures 7a and 7b, respectively).
However, a substantial proportion of the tumours with-
out identified VHL inactivation still display high expres-
sion of CAIX and miR-210. Whilst it is possible that
our mutational and methylation analysis did not identify
all of the causes of VHL inactivation present in these
tumours, it indicates that they may have other genetic
mutations that influence VHL or HIF expression or
function. These mechanisms potentially include disrup-
tions in SETD2 (histone H3K36 methyltransferase) or
JARID1C (histone H3K4 demethylase), which have both
been recently identified as having truncating mutations
in approximately 3% of cc RCC tumours [54]. Other
potential mechanisms of VHL suppression might be
mediated via miRNAs, as has been reported recently for
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miR-92 in chronic lymphocytic leukaemia [55]. The
mechanisms leading to cc RCC tumour initiation and/or
activation of hypoxic pathways in tumours without VHL
mutation or VHL promoter methylation are not well
understood, and further work is needed.
Correlation of miRNA level with clinical features
Overall the 5-year survival in the 31 cc RCC patients was
71%. A significant inverse correlation was found between
miR-210 expression in cc RCC tumours and survival
(years) (r = -0.481, P = 0.006) (Figure 8a). Weaker inverse
correlations were also found between miR-21, let-7i and
miR-18a expression in cc RCC tumour tissue and survival
(years) (r = -0.308, P = 0.09; r = -0.339, P = 0.062; and r =
-0.300, P = 0.101, respectively); however, the correlations
did not achieve statistical significance. No correlation
was found between miR-155 expression and survival (Fig-
ure 8b). The expected correlations between tumour size,
grade, TNM stage and survival (years) were found (r =
-0.572, P = 0.001; r = -0.354, P = 0.055; and r = -0.46, P =
0.031, respectively).
A significant correlation was also found between miR-
155 and miR-21 expression in cc RCC tumours and
tumour size (mm) (r = 0.408, P = 0.028; r = 0.434, P =
0.019, respectively) shown in Figures 8c and 8d. Correla-
tions were also observed for miR-210 and let-7i expres-
sion and tumour size (mm); however, these correlations
did not achieve statistical significance (r = 0.356, P =
0.058; and r = 0.363, P = 0.053, respectively). No corre-
lations were found between miRNA expression in cc
RCC tumours and tumour grade or TNM stage.
These results indicate the ability of levels of specific
miRNAs to correlate with tumour features and patient
outcome. The ability of levels of miR-210 to provide
prognostic information has also been seen in breast can-
cer [19,20] and head and neck cancers [56]. Figures 9a
and 9b show Kaplan-Meier plots that represent survival
(months) stratified by high/low miR-210 expression and
high/low TNM stage. An association was observed
between both high miR-210 expression and high TNM
stage with decreased survival (log-rank 0.189 and 0.022,
respectively); however, the number of samples analysed
in this study was too small for the miR-210 association
to reach statistical significance. It should be noted that
these are preliminary results and that additional confir-
mation of this result will now be required in other lar-
ger sets of renal cancers. In addition, it should be noted
that in some renal tumours, HIF-2a expression may
dominate and therefore miR-210 may not provide gen-
eral prognostic information for all cc RCC tumours.
Expression of ISCU1/2 in cc RCC tumours
The relationship between miR-210 levels and patient
outcome suggests that miR-210 levels in cancer are not
simply a marker of hypoxia but have a fundamental
influence on tumour behaviour. To understand the
mechanisms for the effects of miR-210 levels on patient
outcome, we wished to study influences on potential
mRNA targets. Computer-based algorithms are capable
of predicting a large number of potential mRNA targets
of particular miRNAs, some of which have been vali-
dated experimentally. We have defined a large number
of potential miR-210 targets using such methodology,
and during the course of this study Chan and colleagues
[57] and subsequently others [58-60] were able to
experimentally validate the regulation of one such pre-
dicted target, ISCU1/2.
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The iron cluster assembly proteins, ISCU1 and ISCU2,
are involved in the biogenesis of [4Fe-4S] and [2Fe-2S]
iron-sulfur clusters, which are implicated in a wide
range of biological processes, including electron trans-
port and mitochondrial oxidation-reduction reactions
[61]. The ISCU protein exists as two splice isoforms in
mammalian cells which share both structural and func-
tional similarities: ISCU1 is located in the cytosol,
whereas ISCU2 is located in the mitochondria [62]. It
has been hypothesised that miR-210 represses the
expression of ISCU1/2 during hypoxic conditions, thus
disrupting mitochondrial function and causing down-
stream metabolic changes within the cell [57-60].
We sought to examine whether the elevation of miR-
210 levels in cc RCC was associated with reduced expres-
sion of ISCU1/2 mRNA. The expression of ISCU1/2 was
analysed in the RCC4 ± VHL cell lines, and it was found
that the expression of ISCU1/2 was significantly reduced
in the RCC4-VHL line by at least fivefold (P = 0.05)
(Additional file 4), in keeping with targeting of ISCU1/2
by increased miR-210 expression. Consistent with this
finding, a miR-210 mimic transfected into RCC4 + VHL
cells to increase miR-210 levels did markedly decrease
the mRNA expression of ISCU1/2 (threefold; P = 0.05)
(Additional file 5a). Likewise, a miR-210 antagomir trans-
fected into RCC4-VHL cells to decrease miR-210 levels
markedly increased the mRNA expression of ISCU1/2
(twofold; P = 0.05) (Additional file 5b).
We therefore studied ISCU1/2 mRNA expression levels in
the panel of renal cancers and found that, as previously
shown, miR-210 expression is significantly upregulated in
tumour tissue compared to normal adjacent tissue (P ≤
0.0001), whereas an inverse expression pattern is observed
for ISCU1/2 mRNA (P ≤ 0.0001) (Figure 10a). A striking
negative correlation of miR-210 expression with ISCU1/2
mRNA in cc RCC tissue was observed, and, interestingly,
this correlation was also observed in normal tissue (r =
-0.679; P ≤ 0.0001) (Figure 10b). This suggests that miR-210
may be involved in the physiological regulation of ISCU1/2
expression levels in normal tissues, as well as in tumours,
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and may contribute to the anaerobic pattern of respiration
seen in renal (and other) tumours [63]. The levels of ISCU1/
2 in renal cancers did not correlate with patient outcome,
indicating that the influence of miR-210 level on patient sur-
vival is not mediated solely via ISCU1/2 regulation and that
other miR-210 targets contribute to tumour aggression.
Conclusions
In this study, we have identified miRNAs which are regu-
lated by VHL in cell culture. For some of these miRNAs,
the regulation was HIF-dependent and for others it was
HIF-independent. This pattern of regulation was also
seen in cc RCC for some of these miRNAs when
compared with normal adjacent renal tissue (miR-210,
miR-155, let-7i and miR-18a). The level of one HIF- and
VHL-regulated miRNA, miR-210, showed marked
increases in expression in the renal cancer tissue, and
expression levels were correlated inversely with patient
survival. The enhanced levels of miR-210 in renal cancer
are likely to be mediated by unrestrained HIF activity,
independent of hypoxia. It suggests that the association
that has been seen in other cancers between miR-210
levels and patient survival is not solely because it is a
marker of tumour hypoxia, but because it influences
tumour behaviour through alterations in gene expression.
Figure 9 Overall survival is associated with miR-210 expression
and tumour node metastasis (TNM) tumour stage. (a) Kaplan-
Meier plot shows the overall survival of renal cancer patients
stratified by high and low miR-210 expression levels. High
expression is defined as above the maximum normal tissue
expression value (P = 0.189; log rank). (b) Kaplan-Meier plot
showing the overall survival of renal cancer patients stratified by
low (Stages 1 and 2) and high (Stages 3 and 4) TNM stage cc RCC
tumours (P = 0.022; log rank). The black line indicates low miR-210
expression or tumour stage, and the grey line indicates high miR-
210 expression or tumour stage.
Figure 10 Expression of ISCU1/2 is negatively correlated with
miR-210 expression. Measurements of ISCU1/2 and miR-210
expression were determined by qPCR and normalised to b-actin or
an average of RNU43 and RNU48 expression. qPCR for each sample
was performed in triplicate. (a) ISCU1/2 mRNA level is decreased in
cc RCC tumours (T) compared to normal adjacent tissue (N) (n =
31), whereas the inverse expression pattern is observed for miR-210
(P ≤ 0.0001). (b) A significant inverse correlation is observed
between the miR-210 and ISCU1/2 expression level in both normal
and tumour tissue (r = -0.679, P ≤ 0.0001) (n = 62). Shaded circles
indicate tumour tissue, and open circles represent adjacent normal
tissue. Data are presented on log10 scales.
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miR-210 levels also showed a correlation with a HIF-
regulated mRNA, CAIX, and with the presence of VHL
mutation or promoter methylation. However, some
tumours without evidence of VHL inactivation also had
elevated miR-210 and CAIX levels, indicating the likely
operation of other mechanisms of HIF activation. We
also found a strong inverse correlation between miR-210
levels and mRNA expression of a miR-210 target gene,
ISCU1/2, which may contribute to the repression of
mitochondrial proteins by VHL and to the anaerobic pat-
tern of respiration seen in renal (and other) tumours.
List of abbreviations
CAIX: Carbonic anhydrase IX; cc RCC: clear cell renal cell carcinoma; DMOG:
dimethyloxalylglycine; HIF: hypoxia-inducible factor; ISCU1/2: Iron-sulfur cluster
assembly protein; miRNA: microRNA; MSP: methylation specific PCR; qPCR:
relative quantitation real-time PCR; RCC: renal cell carcinoma; siRNA: small
interfering RNA; TNM: Tumour Node Metastasis; VHL: von Hippel-Lindau.
Additional material
Additional File 1: Protein expression of HIF-1a and HIF-2a in RCC4
± VHL cells and RCC4 + VHL cells treated with DMOG Immunoblot
of cell extract obtained from RCC4 ± VHL cells and RCC4 + VHL cells
following DMOG treatment (1 mM, 24 hours). More HIF-1a and HIF-2a
expression is seen in the RCC4-VHL cells and the DMOG treated RCC4
+VHL cells compared to RCC4 + VHL cells.
Additional File 2: CAIX expression in RCC4 ± VHL cells and RCC4 +
VHL cells treated with DMOG. Measurements of CAIX mRNA expression
was determined by qPCR and normalised to b-actin mRNA expression.
qPCR for each sample was performed in triplicate. Expression of CAIX
was found to be increased in RCC4-VHL cells and RCC4 + VHL cells
treated with DMOG (1 mM, 24 hours) compared to RCC4 + VHL cells (P
= 0.05).
Additional File 3: Table S1. Summary of genetic changes found in
VHL. The mutation nomenclature is in accordance with HGVS (Human
Genome Variation Society) recommendations [31]. Nucleotide numbering
is in accordance with GenBank mRNA sequence [GenBank:L15409] with
the A of the first initiator ATG being 1. Previous descriptions of
mutations were ascertained from http://www.umd.be[64], [33] and [65].
N* indicates that precise mutation has not been reported; however,
similar mutations involving the same codon have been described. Key:
del-deletion, ins-insertion, MS-missense, FS- frameshift, N-nonsense, spl-
splice error.
Additional File 4: Expression of ISCU1/2 in RCC4+/-VHL cells
Measurements of ISCU1/2 expression was determined by qPCR and
normalised to b-actin mRNA expression. qPCR for each sample was
performed in triplicate. (a) ISCU1/2 mRNA level is decreased in RCC4-VHL
cells compared to RCC4 + VHL cells (P = 0.05).
Additional File 5: Expression of ISCU1/2 following miR-210
overexpression and repression Measurements of ISCU1/2 expression
were determined by qPCR and normalised to b-actin mRNA expression.
qPCR for each sample was performed in triplicate. (a) ISCU1/2 expression
level was decreased in RCC4+VHL cells transfected with a miR-210 mimic
compared to untransfected RCC4 + VHL cells and RCC4 + VHL cells
transfected with a negative control (P = 0.05). (b) ISCU1/2 expression
level was increased in RCC4-VHL cells transfected with a miR-210
antagomir compared to untransfected RCC4-VHL cells and RCC4-VHL
cells transfected with a negative control (P = 0.05).
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